SecBot SecBot
8-K ·Filed Aug 5, 2026

BCRX

BIOCRYST PHARMACEUTICALS INC
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001171843-26-005223
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The headline beat is significant but driven by a one-time $55.7M licensing fee, not core ORLADEYO acceleration. ORLADEYO guidance was maintained, not raised, suggesting limited upside to the base business. The lowered opex guidance and pipeline rationalization are credit-positive for cash flow. Watch for navenibart ALPHA-ORBIT data in Q3 2027 as the next major catalyst; the pediatric ORLADEYO pellet launch is a near-term volume driver to monitor.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

BCRX drug pipeline →

navenibart

◆ Mixed Named in this 8-K
Impact
Phase
Phase 3
Time to market
Assuming positive Phase 3 data (Q3 2027), a US regulatory filing would follow around end-2027, with potential approval in 2028-2029.
Next catalyst
None dated

What to watchNavenibart is a promising long-term pipeline story within BioCryst, but there is no imminent binary catalyst for ~12+ months. Investors should watch for interim data updates at medical conferences and the pivotal Phase 3 ALPHA-ORBIT readout in Q3 2027. In the meantime, near-term BCRX value is driven by ORLADEYO commercial execution and the ongoing business restructuring.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.07
T+0 close · Aug 5, 2026 · via day close
Latest settled
−6.73%
T+60 · $8.46
Vs SPY
−6.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $9.07entry
  2. T+1 · 3mo ago +2.54%α +2.70% · $9.30
  3. T+5 · 3mo ago +16.76%α +16.41% · $10.59
  4. T+20 · 3mo ago +12.13%α +12.73% · $10.17
  5. T+60 · 19d ago −6.73%α −6.92% · $8.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioCryst reported Q2 2026 GAAP EPS of $0.30, beating the $0.23 consensus by 30.4%, and total revenue of $218.3M, beating the $183.3M estimate by 19.1%. The beat was driven by a $55.7M navenibart licensing fee from Neopharmed Gentili, while core ORLADEYO revenue grew only 1% YoY to $158.2M. The company raised total revenue guidance to $690M-$715M and lowered non-GAAP opex guidance, but maintained ORLADEYO guidance at $625M-$645M, signaling the core business is not accelerating.

Key Financial Metrics

EPS
$0.30
est $0.23 · +30.4%
Revenue
$218.3M
est $183.3M · +19.1% · +33.6% YoY
Rating
strong beat
Guidance
$690M-$715M
raised

Key Facts

  • GAAP EPS of $0.30 beat consensus of $0.23 by 30.4%
  • Total revenue of $218.3M beat consensus of $183.3M by 19.1%
  • ORLADEYO revenue of $158.2M grew only 1% YoY (10% on comparable basis ex-Europe)
  • Recognized $55.7M of navenibart licensing revenue from Neopharmed Gentili upfront payment
  • Raised full-year 2026 total revenue guidance to $690M-$715M (from $635M-$660M)
  • Maintained ORLADEYO revenue guidance at $625M-$645M
  • Lowered non-GAAP operating expense guidance to $420M-$440M (from $450M-$470M)
  • GAAP operating profit of $98.5M; Non-GAAP operating profit of $113.2M
  • Cash, cash equivalents and investments totaled $352.6M at June 30, 2026
  • Completed enrollment in ALPHA-ORBIT pivotal navenibart study; top-line data expected Q3 2027
  • Began shipping ORLADEYO oral pellets to pediatric patients on August 3, 2026
  • Announced discontinuation of internal discovery programs and closure of Birmingham facility

Financial Impact

Q2 2026 GAAP EPS of $0.30 vs $0.23 consensus (beat by $0.07); total revenue of $218.3M vs $183.3M consensus (beat by $35.0M)

epsrevenueguidanceoperating expenses

Risk Factors

  • Core ORLADEYO revenue growth is decelerating (1% YoY reported, 10% comparable) and guidance was not raised
  • Navenibart is still investigational with pivotal data not expected until Q3 2027, binary risk
  • Restructuring/discontinuation of internal discovery programs may signal limited pipeline depth
  • Stockholders' deficit of $454.3M and accumulated deficit of $2.15B indicate ongoing balance sheet weakness

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-005223
Document: f8k_080526.htm0001171843-26-005223
Document: 0001171843-26-005223-index-headers.html0001171843-26-005223
Document: 0001171843-26-005223-index.html0001171843-26-005223
Document: 0001171843-26-005223.txt0001171843-26-005223
8-K Data (Synthetic)0001171843-26-005223

Track record

20 reports on BCRX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
  2. Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
  4. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
  7. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
  8. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
  9. Aug 5, 202614w ago 8-K Bullish 7/10 Viewing Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
  10. Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026